Nurix Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$16.93(as of May 4, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Nurix Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$16.93
Ticker SymbolNRIX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees317
CountyUSA
Market Cap$1,738.3M
EBIDTA-307.3M
10-Day Moving Average16.69
P/E Ratio-6.31
20-Day Moving Average16.58
Forward P/E Ratio0.00
50-Day Moving Average15.88
Earnings per Share-3.17
200-Day Moving Average14.12
Profit Margin-1,394.34%
RSI56.28
Shares Outstanding103.4M
ATR0.82
52-Week High22.50
Volume551,917
52-Week Low8.20
Most Recent Support Level16.20
Book Value480.9M
Most Recent Resistance Level17.21
P/B Ratio3.88
Upper Keltner18.43
P/S Ratio25.96
Lower Keltner14.73
Debt-to-Equity Ratio18.43
Next Earnings DateUnknown
Cash Surplus-21.0M
Next Ex-Dividend DateUnknown

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Nurix Therapeutics Inc In Our Stock Scanner

As of May 05, 2026
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Falling WedgeScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.